Clinical Report: Multiparametric Prostate MRI in Clinical Practice and Focal Therapy

Overview

Multiparametric MRI (mpMRI) significantly improves detection and characterization of clinically significant prostate cancer (PCa), aiding in patient selection and treatment planning for focal therapy (FT). An international Delphi consensus among experts supports standardized mpMRI protocols and highlights the value of MRI-TRUS fusion targeted biopsies in enhancing diagnostic accuracy and surveillance.

Background

Advancements in mpMRI, incorporating T1-2 weighted imaging, dynamic contrast-enhanced (DCE), and diffusion-weighted imaging (DWI), have enhanced the detection of clinically significant PCa. Standardized reporting systems such as PI-RADS v2 are recommended to ensure quality and reproducibility. MpMRI shows high positive and negative predictive values when compared to pathology, especially in expert centers with standardized acquisition and interpretation. MRI-TRUS fusion targeted biopsies improve detection rates of significant PCa and reduce detection of insignificant tumors, supporting their use in both diagnosis and follow-up after focal therapy.

Data Highlights

Key Findings

• MpMRI provides high positive predictive values (up to 98%) and negative predictive values (up to 90%) for detecting clinically significant PCa, especially in expert centers.
• MpMRI-TRUS fusion targeted biopsies improve detection rates of clinically significant PCa and reduce detection of insignificant tumors compared to standard TRUS biopsies.
• Standardized mpMRI acquisition and reporting protocols (e.g., PI-RADS v2) are widely adopted by clinicians (96%) and recommended for clinical practice and research.
• Expert consensus strongly discourages use of 1.5 Tesla MRI scanners without an endorectal coil or pelvic phased-array coil due to inferior image quality.
• Repeated mpMRI is recommended during surveillance following focal therapy to monitor disease status.
• The Delphi consensus process engaged a multidisciplinary panel with extensive clinical experience, validating the recommendations for mpMRI use in PCa diagnosis and focal treatment planning.

Clinical Implications

Clinicians should utilize multiparametric MRI with standardized protocols and MRI-TRUS fusion targeted biopsies to improve detection and characterization of clinically significant prostate cancer. Use of appropriate MRI hardware, such as 3 Tesla scanners or 1.5 Tesla with endorectal coils, is essential for optimal imaging quality. Repeated mpMRI is valuable for monitoring patients after focal therapy, aiding in early detection of recurrence or progression.

Conclusion

Multiparametric prostate MRI, combined with MRI-TRUS fusion targeted biopsies, represents a critical advancement in the diagnosis and management of prostate cancer, particularly for focal therapy. Adoption of standardized imaging protocols and expert consensus recommendations will enhance clinical outcomes and patient selection.

References

1. PI-RADS v2 -- Prostate Imaging Reporting and Data System
2. Study on PPV and NPV of mpMRI with 3D mold pathology correlation [2]
3. PPV and NPV for lesion volumes >0.2 mL and >0.5 mL [3]
4. Overview tables on mpMRI PCa detection [4,5]
5. Systematic review on NPV range of mpMRI [6]
6. PPV of mpMRI for index lesion in focal therapy [7]
7. Detection rates of index and Gleason ≥7 tumors by mpMRI [8]
8. Comparison of mpMRI-TRUS fusion targeted biopsies vs TRUS biopsies [9]
9. Delphi consensus methodology [19]